XELJANZ Drug Insight

“XELJANZ Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about XELJANZ for Psoriatic Arthritis (PsA) in the seven major markets. A detailed picture of the XELJANZ for psoriatic arthritis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the XELJANZ for psoriatic arthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XELJANZ market forecast analysis for psoriatic arthritis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in psoriatic arthritis.

Drug Summary

XELJANZ/XELJANZ XR (Tofacitinib) is formulated with the citrate salt of tofacitinib, a JAK inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity, including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.

It is indicated for treating adult patients with active PsA who have inadequate responses or intolerance to MTX or other DMARDs. However, using XELJANZ/XELJANZ XR combined with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. The recommended dosage for patients with PsA is 5 mg twice daily or XELJANZ XR 11 mg once daily. For patients with moderate and severe renal impairment or moderate hepatic impairment, XELJANZ 5 mg is given once daily.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the XELJANZ description, mechanism of action, dosage and administration, research and development activities in psoriatic arthritis.
• Elaborated details on XELJANZ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XELJANZ research and development activities in psoriatic arthritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around XELJANZ.
• The report contains forecasted sales of for psoriatic arthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for psoriatic arthritis.
• The report also features the SWOT analysis with analyst views for XELJANZ in psoriatic arthritis.
• Methodology
• The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XELJANZ Analytical Perspective by DelveInsight

In-depth XELJANZ Market Assessment

This report provides a detailed market assessment of XELJANZ for psoriatic arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

XELJANZ Clinical Assessment

The report provides the clinical trials information of XELJANZ for psoriatic arthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for psoriatic arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XELJANZ dominance.
• Other emerging products for psoriatic arthritis are expected to give tough market competition to XELJANZ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XELJANZ in psoriatic arthritis.
• Our in-depth analysis of the forecasted sales data of XELJANZ from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XELJANZ in psoriatic arthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of XELJANZ?
• What is the clinical trial status of the study related to XELJANZ in psoriatic arthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XELJANZ development?
• What are the key designations that have been granted to XELJANZ for psoriatic arthritis?
• What is the forecasted market scenario of XELJANZ for psoriatic arthritis?
• What are the forecasted sales of XELJANZ in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to XELJANZ for psoriatic arthritis?
• Which are the late-stage emerging therapies under development for the treatment of psoriatic arthritis?